



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/586,863	07/21/2006	Tiberio Bruzzese	293412US0PCT	1570

22850 7590 05/25/2010
OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, L.L.P.
1940 DUKE STREET
ALEXANDRIA, VA 22314

EXAMINER

KIM, JENNIFER M

ART UNIT	PAPER NUMBER
----------	--------------

1628

NOTIFICATION DATE	DELIVERY MODE
-------------------	---------------

05/25/2010

ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com
oblonpat@oblon.com
jgardner@oblon.com

Office Action Summary	Application No. 10/586,863	Applicant(s) BRUZZESE, TIBERIO	
	Examiner JENNIFER M. KIM	Art Unit 1628	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on April 5, 2010.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 29-49 is/are pending in the application.
- 4a) Of the above claim(s) 32 and 33 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 29-31 and 34-49 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|----------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>7/21/2006</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Applicant's election with traverse of Group I, claims 29-31 and 34-49 drawn to a method of using a composition for the preparation of a drug for the prevention and/or treatment of schizophrenia is acknowledged. The traversal is on the ground(s) that the Office has not met the burden necessary to support making the lack of unity requirement because the Office has not provided any indication that the contents of the claims interpreted in light of the description considered under Annex B of the Administrative Instructions under the PCT (b) nor MPEP 806.03. This is not persuasive because the reasons of making the lack of unity requirement was clearly stated in the previous restriction requirement because the inventions of Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because under PCT Rule 13.2, they lack the same or corresponding special technical features due to each of the medical disorders being treated have different etiology and has different known treatment, for example, the treatment of Alzheimer's disease involving etiology associated with beta amyloid protein deposits is completely different than the treatment involving depression associated with cholinergic nervous system. Therefore, the lack of unity made in the previous Office Action is deemed proper and made final.

Accordingly, claims 29-31 and 34-49 are being examined and claims 32 and 33 are withdrawn from consideration since they are non-elected invention.

Claim Rejections - 35 USC § 112

1. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Enablement

2. Claims 29-31 and 34-49 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for “a method of using a composition for the preparation of a drug for . . . **treatment** of psychiatric disturbances”, does not reasonably provide enablement for “**preventing** ...the psychiatric disturbances”. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims.

3. Enablement is considered in view of the Wands factors (MPEP 2164.01(a)). These include: the nature of the invention, breadth of the claims, guidance of the specification, the existence of working examples, predictability of the prior art, state of the prior art and the amount of experimentation necessary. All of the **Wands factors** have been considered with regard to the instant claims, with the most relevant factors discussed below.

Nature of the Invention: All of the rejected claims are drawn to a method of using a composition for the preparation of a drug for the prevention and/or treatment of the psychiatric disturbances of the central nervous system (CNS) selected from the group consisting of schizophrenia comprising a component

Art Unit: 1628

selected from the group consisting of DHA in admixture with eicosapentaenoic acid (EPA, C20:5 n-3), in a ratio of 1:0.5 to 1:1.7, respectively, and/or the pharmaceutically acceptable derivatives and/or precursors thereof; wherein said component is present in a concentration not lower than 70% by weight of the total fatty acids weight in the composition with the proviso that it does not comprise 10 to 40% by weight of reducing/antioxidant vitamins or provitamins. The nature of the invention is extremely complex in that it encompasses the **actual prevention** of a psychiatric dysfunction (i.e. schizophrenia) such that the subject treated with the above compounds does not contract schizophrenia.

Breath of the Claims: The complex of nature of the claims is greatly exacerbated by breath of the claims. The claims encompass **prevention** of a disorder that is understood very little in terms of specific etiology.

Guidance of the Specification: The guidance given by the specification as to how one would administer the claimed compounds to a subject in order to actually **prevent** schizophrenia is minimal. All of the guidance provided by the specification is directed towards **treatment** of schizophrenia rather than the **prevention**.

Working Examples: All of the working examples provided by the specification are directed toward the treatment rather than prevention of schizophrenia.

State of the Art: While the state of the art is relatively high with regard to treatment of psychological dysfunction (i.e. depression, anxiety, schizophrenia), the state of the art with regard to **prevention** of such disorders is

Art Unit: 1628

underdeveloped. In particular, there do not appear to be any examples or teachings in the prior art wherein a compound similar to the claimed compounds was administered to a subject to **prevent** development of schizophrenia.

Predictability of the Art: The lack of significant guidance from the specification or prior art with regard to the actual **prevention** of schizophrenia in a human subject with the claimed compounds makes practicing the claimed invention unpredictable in terms of **prevention** of schizophrenia.

The amount of Experimentation Necessary: In order to practice the claimed invention, one skilled in the art would have to first envision a combination of appropriate pharmaceutical carrier, compound dosage, duration of treatment, route of administration, etc. and an appropriate animal model system for one of the claimed compounds and then test the combination in the model system to determine whether or not the combination is effective for **prevention** of schizophrenia. If unsuccessful, which is likely given the lack of significant guidance from the specification or prior art regard prevention of schizophrenia with any compound, one of skill in the art would have to then either envision a modification of the first combination of pharmaceutical compound, compound dosage, duration of treatment, route of administration, etc. and appropriate animal model system, or envision an entirely new combination of the above, and test the system again. If again unsuccessful, which is likely given the lack of significant guidance form the specification or any prior art regarding prevention of schizophrenia with compound, the entire, unpredictable process would have to

Art Unit: 1628

be repeated until successful. Therefore, it would require undue, unpredictable experimentation to practice the claimed invention to prevent the development of schizophrenia in a subject by administration of one of the claimed compounds.

Therefore, a method of using a composition for the preparation of a drug for the **prevention** and/or treatment of the psychiatric disturbances of the central nervous system (CNS) selected from the group consisting of schizophrenia comprising a component selected from the group consisting of DHA in admixture with eicosapentaenoic acid (EPA, C20:5 n-3), in a ratio of 1:0.5 to 1:1.7, respectively, and/or the pharmaceutically acceptable derivatives and/or precursors thereof; wherein said component is present in a concentration not lower than 70% by weight of the total fatty acids weight in the composition with the proviso that it does not comprise 10 to 40% by weight of reducing/antioxidant vitamins or provitamins is **not** considered to be enabled by the instant specification.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Art Unit: 1628

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 29-31 and 34-49 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nishikawa et al. (U.S. Patent No. 6,306,907 B1) and Horrobin (U.S. Patent No. 4,977,187) and further in view of Chen (U.S. Patent No. 6,759,435 B1).

Nishikawa et al. teaches an oral antipsychotic comprising at least one of docosahexaenoic acid or derivatives thereof as an active ingredient for treatment of psychosis such as schizophrenia. Nishikawa et al. teaches that such antipsychotic is highly safe and effective and can be formulated as capsules (abstract, column 2, lines 55-63). Nishikawa et al. teach that ethyl esters of docosahexaenoic acids can be employed as derivatives (column 2, lines 21-30). Nishikawa et al. teaches that for the oral administration the clinical dose of the active ingredient is preferably from 300mg to 1800 mg per day for adult subjects and can be administered once a day, or twice or three times a day at suitable intervals. (column 3, lines 25-33). Nishikawa et al. teach that the antipsychotic can be suitably administered together with the other suitable antipsychotics, for example haloperidol (column 3, lines 10-15). Nishikawa et al. teach that schizophrenia and its symptoms can be classified into two types, positive symptoms such as hallucinations, delusions, and abnormal behaviors and negative

Art Unit: 1628

symptoms such as catatonia, autism, and non-emphasis. Nishikawa et al. teach that there is a need for a drug which can improve not only positive symptoms of schizophrenia but also its negative symptoms which causes no side effect. (column 1, lines 10-30). Nishizawa et al. exemplify that the antipsychotic of DHA showed improvements in negative symptoms of schizophrenia (example 2).

Horrobin exemplifies a capsule containing 200mg purified GLA (gamma linolenic acid: n-6) and 200mg purified EPA for treatment of schizophrenia, 2 to 8 capsules to be taken per day. It is noted that the daily dosage of EPA ranges 400mg to 1600mg per day. (column 6 example A, 2). Horrobin teaches that in the treatment of schizophrenia, composition can be formulated with or **without vitamin E** (column 4, lines 13-25).

Chen teaches that the term schizophrenia encompasses paranoid, disorganized, catatonic, and undifferentiated schizophrenia. (column 7 line 65 to column 8 line 5).

The claims differ from the cited references in claiming combination of DHA and EPA and GLA composition of Horrobin to treat schizophrenia. To employ combinations of DHA and EPA & GLA (gamma-linolenic acid: n-6 essential fatty acid) composition to treat schizophrenia would have been obvious because all the components are well known individually for treating schizophrenia. It would be expected that the combination of components would schizophrenic conditions as well. One of ordinary skill in the art would have combined the antischizophrenic agents by known methods and that in combination, each element merely would have performed the same antischizophrenic activity as it did separately. The convenience of putting the compounds having the same antischizophrenic activity of DHA and EPA & GLA

Art Unit: 1628

composition together in one dosage form, though perhaps a matter of great convenience does not produce a "new" or "different" function and to those skilled in the art, the use of the old elements in combination would have been obvious. The motivation for combining the components flows from their individually known common utility (see *In re Kerkhoven*, 205 USPQ 1069(CCPA 1980)). The ratio of DHA in admixture with EPA set forth in claims 29 and 34, the dosages set forth in claims 45-47, and the concentration of DHA and EPA by weight of the total fatty acids weight in the composition set forth in claims 35-37 are noted however, the ratio is within the therapeutic amount of each of the agents for the treatment of schizophrenia in the obvious combination. Further, no unobviousness is seen in the concentrations claimed because once the usefulness of a compound is known to treat a condition, it is within the skill of the artisan to determine the optimum concentration. The formulation of soft gelatin capsules set forth in claim 44 is noted, however, such is obvious because both cited reference teach that the active agents can be formulated in capsules in general. Therefore, the soft gelatin capsule would be an obvious variation of capsules form taught by the prior art without a surprising and unexpected result. With regard to the specific schizophrenia to be treated set forth in claim 31, such is obvious because cited references teach the treatment of schizophrenia in general which generally encompasses paranoid, catatonic, disorganized or undifferentiated schizophrenia is well known in the art in view of Chen. Thus, the claims fail to patentably distinguish over the state of the art as represented by the cited references.

Communications

Any inquiry concerning this communication or earlier communications from the examiner should be directed to JENNIFER M. KIM whose telephone number is (571)272-0628. The examiner can normally be reached on Monday through Friday 6:30 am to 3 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/JENNIFER M KIM/
Primary Examiner, Art Unit 1628

Application/Control Number: 10/586,863

Page 11

Art Unit: 1628

Jmk

May 18, 2010